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Retroperitoneal lymph node dissection (RPLND) is a prognostic, palliative, and potentially therapeutic procedure
for patients with malignant phenotype Leydig cell tumours of the testis. We reviewed the records of patients
diagnosed with malignant phenotype Leydig cell tumours of the testis treated by RPLND. Modified template
dissection was performed in all cases with extra-template excision of tumour mass in Stage II disease. Routine
clinico-radiological follow-up was performed. Six open RPLNDs (1 re-do procedure) were performed on 5 patients
diagnosed with Stage I (n = 3) and Stage II (n = 2) malignant phenotype Leydig cell tumour of the testis. Median
age = 63 years (range = 55-72). Median peri-operative blood loss = 1500 ml (range = 500-1500 ml). Median
operating time = 6 h (range = 4.5-6.5). Two patients with Stage II disease developed post-operative complications
of acute kidney injury (n = 1) and pneumonia (n = 1). Median length of stay was 8 days (range = 6-11). RPLND
specimens from patients with Stage I were tumour-free, whilst patients with Stage II disease had evidence of
metastatic tumour. At latest follow-up (median = 13 months, range = 7-22), no patient with Stage I disease had
radiological evidence of recurrence, however the two patients with Stage II disease had died due to tumour recurrence
at 13 months and 36 months. RPLND for malignant phenotype Leydig cell testicular tumours appears to be well
tolerated. Despite surgery, overall outcomes for Stage II appear to be poor due to the disease phenotype. Larger
prospective multi-centre studies are required to determine the definitive criteria for surgery in Stage I disease.
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Testicular cancer is a relatively rare malignancy with ~2200
new cases diagnosed each year in the UK (Testicular cancer
incidence statistics 2014). In Scotland, ~200 new cases
are diagnosed each year with a 93.4% overall crude 5-year
survival rate (Summarised cancer mortality, male genital
organs 2014), largely as a result of contemporary chemo-
therapy strategies. Germ cell tumours represent the com-
monest histological subtype, and rarer variants include sex
cord/gonadal stromal tumours and non-specific stromal
tumours with both benign and malignant disease pheno-
types (Albers et al. 2011).
Leydig cell tumours are gonadal stromal tumours that
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in any medium, provided the original work is pare the most common non-germ cell testicular tumour
(Cheville 1999). Whilst the majority have benign clinical
course, and can be fully treated by local excision or radical
inguinal orchidectomy, arguably 10% are recognized to
have a malignant phenotype with metastatic potential
based upon the presence of specific histopathological fea-
tures (Albers et al. 2011) (Table 1). Similar to germ cell
tumours, the route of spread is haematogenous and lymph-
atic to the retroperitoneal lymph nodes, but unlike germ
cell tumours there is relative lack of sensitivity to radiothe-
rapy and chemotherapy agents (Farkas et al. 2000).
Retroperitoneal lymph node dissection (RPLND) can
be performed subsequent to orchidectomy in patients
with both organ-confined and metastatic disease, and
serves as a prognostic, palliative, and potentially thera-
peutic procedure. The outcomes of RPLND for malig-
nant Leydig cell tumours of the testis have been limited
to a few case series (Silberstein et al. 2014; Di Tonnoan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Histopathological features suggesting a
malignant phenotype of a testicular Leydig cell tumour
(Albers P, Albrecht W, Algaba F, Bokemeyer C,
Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP,
European Association of U 2011)
Number Features
I. Large Tumour size (>5 cm)
II. Cytological atypia
III. Increased mitotic activity (>3 per 10 high power field [HPF])




VIII. Extension beyond the testicular parenchyma
IX. DNA aneuploidy
Hendry et al. SpringerPlus  (2015) 4:20 Page 2 of 7et al. 2009; Mosharafa et al. 2003; Peschel et al. 2003).
Here, we present our national Scottish experience of
RPLND for malignant phenotype Leydig cell tumours
of the testis.
Patients and methods
Between 2004 and 2014, all males within Scotland diag-
nosed with malignant phenotype Leydig cell tumours of
the testis deemed suitable for surgery were referred to
our specialist centre for consideration of open RPLND
performed by a single surgeon. Diagnosis, determination
of disease phenotype, and suitability for major surgery
was made in local referring centres by histopathological
assessment of the primary orchidectomy specimen as
per European and UK guidelines (Albers et al. 2011;
Standards and datasets for reporting cancers. Dataset for
the histological reporting of testicular neoplasm 2014)
prior to referral to our centre. All patients were reviewed
clinically to verify suitability for surgery and primary
orchidectomy specimens were subjected to centralised
histopathology review to confirm histological features.
Clinico-pathological parameters were recorded centrally
including patient demographics, symptoms, tumour mar-
kers (α-fetoprotein protein [α-FP], β-human chorionic
gonadotrophin [β-hCG], lactate dehydrogenase [LDH]),
histopathology, and radiological staging by computed
tomography (CT) and, where available, positron emission
tomography CT (PET-CT). Clinical stage, as per TNM
created by the American Joint Committee on Cancer
(AJCC) was recorded based on preoperative clinical sta-
ging (Testis 2010). Following case review by the specialist
testis multi-disciplinary team, patients were offered
RPLND. Pre-operative sperm banking was offered in local
referring centres as per National Guidelines (SIGN 2011).
For all patients, open RPLND with modified unilate-
ral template dissection was performed, as previouslydescribed by the Indiana group (Donohue et al. 1982),
which involves removal of lymphatic tissue from the right
paracaval, precaval, and interaortocaval areas for right-
sided tumours and left para-aortic and pre-aortic areas for
left-sided tumours. Additional extra-template excision
of tumour mass in Stage II disease was also performed
where indicated by pre-operative imaging. Where pos-
sible, nerve-sparing procedures was performed to pre-
serve ejaculatory function. Subsequent follow-up was
undertaken in local referring centres and comprised CT
imaging, serum tumor markers and clinical examin-
ation on an initial 3–6 monthly schedule.
Results
Between 2004 and 2014, we performed 6 RPLNDs on 5
patients (including 1 re-do procedure) diagnosed with
Stage I (n = 3) and Stage II (n = 2) malignant phenotype
Leydig cell tumour of the testis. The median age at diag-
nosis was 63 years (range = 55-72), and there were 4
right-sided and 2 left-sided modified template RPLNDs
performed. Clinico-pathological characteristics of the pa-
tient cohort are given in Table 2. Pre-operative testicular
tumour markers were found to be within normal limits
in all cases. No patient had any endocrine symptoms,
therefore pre-operative biochemical assessment was not
performed. Of the patients with Stage II disease (n = 2),
only 1 patient had pre-operative chemotherapy (4 cycles
of Bleomycin, Etoposide and Cisplatin), but had residual
retroperitoneal disease on post-treatment radiological
imaging signifying a poor treatment response. No patient
with Stage I disease was subjected to pre-operative
chemotherapy.
Although pre-operative ejaculatory function data was
not available, a standard modified unilateral template
dissection was performed for all cases of Stage I disease
with attempted nerve-sparing to preserve post-ganglionic
sympathetic fibres for ejaculatory function. For Stage II,
an extended dissection was performed to completely re-
sect the tumour mass as indicated by pre-operative im-
aging. Peri-operative details are given in Table 2, however
there was no major peri-operative vascular or visceral
injury. Median peri-operative blood loss was 1500 ml
(range = 500-1500 ml) and median operating time 6 hours
(range = 4.5-6.5).
One patient with Stage II disease (Case 1) had exten-
sive involvement of the right ureter in tumour mass and
therefore nephrectomy was performed. One patient with
Stage II disease developed post-operative complications
of acute kidney injury (Case 3) and one patient with
Stage I disease developed pneumonia (Case 5). The median
length of stay was 8 days (range = 6-11). On histopatho-
logical assessment, resected specimens from patients with
Stage I were tumour-free, whilst patients with Stage II dis-
ease had evidence of metastatic tumour in the RPLND
Table 2 Peri-operative patient characteristics
Case Age [Side] Path. features from
Table 1 (Total)






Pathology at RPLND Recurrence DFS (months)
1 (63) Right I, II, III, VI, VIII (5) aFP 2bHCG<2 LDH 183 IIA (Ipsilateral
Paraortic nodal
uptake)
1500 6 Nil 11 LCT (180x65x25mm)
Involvement of right
ureter-> nephrectomy
Yes N/A (died at
13 months)
2 (55) Left II, III, V (3) aFP 3bHCG<2 LDH 210 I 500 6 Nil 8 Benign No 7 months
3 (72) Left I, II, V, VI (4) aFP 4bHCG<3 LDH 214 IIB (Ipsilateral
Paraortic nodes,
up to 5cm)





4 (67) Right I, III (2) aFP 6bHCG<3 LDH 186 I 1500 5.5 No 6 Benign No 23 months
5 (61) Right II (1) aFP 3bHCG<3LDH 222 I 800 4.5 Pneumonia 9 Benign No 16 months
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tion was not available for all patients.
At latest follow-up (median = 13 months, range = 7-22),
no patient with Stage I disease had radiological evidence
of recurrence, however patients with Stage II disease had
died due to tumour recurrence at 13 months and 36
months. One of the patients with Stage II disease (Case 3)
developed an early left-sided pelvic recurrence adjacent to
the mesentery of this sigmoid colon and ureter, and re-
quired re-resection with ureteric reconstruction with a
Boari flap at 16 months post primary surgery. Figures 1
and 2 demonstrates this patient’s initial CT scan, as well
as histopathology of the primary testicular tumour and
resected metastases from the initial RPLND.
Discussion
Malignant phenotype Leydig cell tumours typically pre-
sent in older men with a reported median age of 62.1
(range 39–70) years (Gonzalez et al. 2007), which is
similar to our cohort. The normal endocrine function of
the Leydig cell may result in elevated serum and urine
sex hormone levels during tumourigenesis however, the
clinical symptoms related to hormone excess are less
common. Signs and symptoms of hormone excess may
precede identification of a testicular mass, and in youn-
ger patients precocious puberty may be the initial symp-
tom, with gynaecomastia being a clinical sign in older
patients (Gana et al. 1995; Ozyavuz et al. 1993).Figure 1 CT scan demonstrating retro-peritoneal tumour. Abdominal C
side to original primary tumour. RPLND yielded a 120x85x40mm mass whicLeydig cell tumours are historically quoted as having
10% risk of malignant phenotype with metastatic poten-
tial (Cheville et al. 1998; Kim et al. 1985). An increase in
the number of incidental focal testicular lesions, identi-
fied by wider use of scrotal ultrasonography, of which
the majority are benign (Carmignani et al. 2003), has led
to the suggestion that metastatic rates of Leydig cell tu-
mours may be less than traditionally thought. Hence,
organ-sparing surgery by local excision in young patients
with low risk disease is a potential therapeutic option
(Heer et al. 2010; Loeser et al. 2009). However, the con-
fident pre-operative prediction of a benign phenotype is
challenging based upon current diagnostic modalities.
Given the tumour’s overall rarity and low malignant
potential, and refractory response to radiotherapy and
chemotherapy, there is still controversy over optimal
treatment. One potential reason for this is the lack of
unequivocal histopathological criteria for a malignant
phenotype. Although the only universally-recognized
hallmark of a malignant phenotype is the presence of
metastasis, there are 9 overall features of the primary
tumour thought to be indicative (Table 1), although not
all of these needs to be present in tumours that me-
tastasize (Grem et al. 1986). In our series, all patients
with histopathologically-confirmed Stage II disease had
only 4 or 5 of these criteria. However, in a series (n = 29)
of young (median = 43 years) patients who underwent
primary surgery alone, only five patients expressed anyT scan from Case 3 highlighting retroperitoneal mass on ipsilateral
h was histologically confirmed as metastatic Leydig cell tumour.
(A) (B)
(C) (D) (E)
Figure 2 Histopathology slides of primary and metastatic Leydig cell tumour. Sample obtained from Case 2. (A) Haematoxylin and Eosin
(H&E) image demonstrating tumour in orchidectomy specimen (×1.25 magnification). (B) H&E image demonstrating severe cytological atypia in
testicular primary (×20 magnification. (C) H&E image demonstrating tumour in mass from RPLND (×200 magnification). (D) Immunohistochemical
staining of RPLND specimen demonstrating expression of Inhibin (×40 magnification). (E) H&E image demonstrating tumour RPLND specimen
(×20 magnification).
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et al. 2009). Furthermore, no metastases were observed
over a median 49-month follow-up period.
The development of metastases typically occurs within
2 years of the initial diagnosis, although has been re-
ported up to 8 years after orchidectomy (Bertram et al.
1991). Metastases have similar histological features to
the original tumour (spreading to retroperitoneal lymph
nodes (70%), liver (45%), lung (40%) and bone (25%), and
are particularly chemo-radio-resistant, with radiation only
effective in some cases to palliate pain symptoms (Bertram
et al. 1991). Hence RPLND may have prognostic, pallia-
tive, and potentially therapeutic application in at risk pa-
tients with Stage I, as well as Stage II disease.
Studies reporting the outcome of RPLND for malignant
phenotype Leydig cell tumours are limited (Silberstein
et al. 2014; Di Tonno et al. 2009; Mosharafa et al. 2003;
Peschel et al. 2003). Mosharfa et al. report outcomes of
RPLND (n = 17) for sex cord stromal tumours, includ-
ing malignant phenotype Leydig cell tumours (n = 6)
(Mosharafa et al. 2003). Three cases had Stage I disease
had were disease-free at latest follow-up (range = 25-135
months), and three cases had Stage II disease at RPLND,
and subsequently died (at range = 11-52 months) despite
further treatment (surgery, chemo- or radio-therapy). The
latter patients had initially presented with Stage I diseaseand were managed by surveillance, highlighting the poten-
tial benefit of early RPLND.
Di Tonno et al. report outcomes of RPLND (n = 5)
undertaken for Stage I (n = 3) and Stage II (n = 2) malig-
nant phenotype Leydig cell tumours (Di Tonno et al.
2009). During follow-up (range = 24-214 months), there
were no recurrences reported. The median age of this
cohort was low (mean = 36 years), and since age is a
poor prognostic factor for Leydig cell tumours (Albers
et al. 2011), one might expect a lower rate of recurrence
and metastatic disease compared with our own patient
cohort. There is only one study of minimally-invasive
(laparoscopic) RPLND for patients with Stage I malig-
nant phenotype Leydig cell tumours (n = 6) with a mean
age of 41 years (range 29–58) (Peschel et al. 2003).
However, there were two intra-operative vascular com-
plications requiring open conversion. During a mean
follow-up of 12 months (range 3–29 months), no recur-
rences were identified.
The most recent series is from Memorial Sloan Kettering
Cancer Centre: Of the 48 patients with sex cord stromal
tumours described, 6 patients with either Stage I (n = 4) or
Stage II (n = 2) malignant phenotype Leydig cell tumours
were managed by RPLND. Interestingly, two patients with
Stage I disease, who harboured 5 pathological features
(Table 2), developed early relapse and died of metastatic
Hendry et al. SpringerPlus  (2015) 4:20 Page 6 of 7disease within 24 months of surgery (of which one had
positive nodal disease), whilst the other 2 remained
disease-free. Of the patients with Stage II disease, one
had recurred but was still alive at 49 months after sur-
gery. The median age of the RPLND-managed cohort
was 48 years (interquartile range = 37-53), and median
follow-up time was 68 months (range = 49-173).
We present the largest UK series of RPLND for ma-
lignant phenotype Leydig cell tumours of the testis. Al-
though limited by a small patient cohort with a short
follow-up period and a lack of functional outcomes,
our experience suggests that RPLND is well tolerated
with minimal toxicity and good disease-free outcomes
in Stage I disease. Our operating time (median = 6 h,
range = 4.5-6.5) and peri-operative blood loss (median =
1500 ml, range = 500-1500 ml) appeared greater than the
parameters from the only report including these out-
comes (mean time = 190 mins, range = 150-225, and mean
estimated blood loss = 110 ml, range = 20-350), but may
be due to the minimally-invasive technique employed
(Peschel et al. 2003). A further limitation of our report is
the absence of information on patients managed in local
centres by surveillance and/or chemotherapy.
Taken together with previously published data, there is
still insufficient evidence to recommend RPLND as stan-
dard of care for all patients. For young patients with very
few (≤1) malignant histological features, a period of ac-
tive monitoring may be considered. However, for older
patients, those with a larger number of malignant histo-
logical features, or those with Stage II disease, RPLND
may, at least, offer good palliation and a possibility of
cure. Larger prospective multi-centre studies, with cen-
tralized histopathological reporting, are required to de-
termine the definitive role for surgery in Stage I disease.
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